Inventor · disambiguated record
David Fairlie
Also filed as: FAIRLIE DAVID · FAIRLIE DAVID P · FAIRLIE DAVID PAUL
16 granted patents·13 pending applications·113 citations·filing 1995–2021
92Inventor score
Top patents by PatentIndex Score
29 records- 0182US7410945B2Treatment of inflammatory bowel diseaseUNIV QUEENSLAND·Filed 2003·Granted Aug 12, 2008·18 cites·9 claims
- 0279US6821950B1Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptorsUNIV QUEENSLAND·Filed 1998·Granted Nov 23, 2004·40 cites·54 claims
- 0377US9586914B2Modulators of C3a receptorsUNIV QUEENSLAND·Filed 2012·Granted Mar 7, 2017·4 cites·26 claims
- 0476US7579432B2Cyclic peptides as G-protein-coupled receptor antagonistsPROMICS PTY LTD·Filed 2002·Granted Aug 25, 2009·10 cites·7 claims
- 0575US8927503B2Modulations of protease activated receptorsFAIRLIE DAVID PAUL·Filed 2011·Granted Jan 6, 2015·7 cites·10 claims
- 0670US6043357AHIV protease inhibitorsUNIV QUEENSLAND·Filed 1995·Granted Mar 28, 2000·21 cites·14 claims
- 0768US10011602B2Immunological reagents and uses thereforUNIV MELBOURNE·Filed 2013·Granted Jul 3, 2018·2 cites·11 claims
- 0866US8193310B2Alpha helical mimics, their uses and methods for their productionFAIRLIE DAVID P·Filed 2005·Granted Jun 5, 2012·1 cites·16 claims
- 0964US8921306B2Nociceptin mimeticsFAIRLIE DAVID·Filed 2011·Granted Dec 30, 2014·3 cites·22 claims
- 1064US7659246B2Treatment of osteoarthritisPROMICS PTY LTD·Filed 2003·Granted Feb 9, 2010·3 cites·19 claims
- 1162US2009203760A1CYCLIC AGONISTS AND ANTAGONISTS OF C5a RECEPTORS AND G PROTEIN-COUPLED RECEPTORSUNIV QUEENSLAND·Filed 2008·Application pending·0 cites
- 1261US2007249526A1Process for the preparation of cyclic peptidesABBENANTE GIOVANNI·Filed 2007·Application pending·0 cites
- 1360US7253194B2Compounds and inhibitors of phospholipasesUNIV QUEENSLAND·Filed 2001·Granted Aug 7, 2007·3 cites·30 claims
- 1460US2010331236A1Cyclic peptides as g-protein coupled receptor antagonistsPROMICS PTY LTD·Filed 2009·Application pending·0 cites
- 1557US2005119167A1Process for the preparation of cyclic peptidesFiled 2004·Application pending·0 cites
- 1656US2006160726A1Cyclic agonists and antagonists of C5a receptors and G protein-coupled receptorsUNIV QUEENSLAND·Filed 2004·Application pending·0 cites
- 1754US2009004264A1Methods for treating and ameliorating the symptons of inflammatory bowel diseasesUNIV QUEENSLAND·Filed 2008·Application pending·0 cites
- 1853US2013005644A1Cyclic agonists and antagonists of c5a receptors and g protein-coupled receptorsPROMICS PTY LTD·Filed 2012·Application pending·0 cites
- 1952US2024109847A1Histone deacetylase inhibitorsUNIV QUEENSLAND·Filed 2021·Application pending·0 cites
- 2051US9701711B2Modulators of protease activated receptorsUNIV QUEENSLAND·Filed 2014·Granted Jul 11, 2017·0 cites·10 claims
- 2149US2012302493A1Cyclic Peptides As G-Protein Coupled Receptor AntagonistsTAYLOR STEPHEN MAXWELL·Filed 2012·Application pending·0 cites
- 2244US8629241B2Alpha helical mimics, their uses and methods for their productionFAIRLIE DAVID P·Filed 2012·Granted Jan 14, 2014·0 cites·22 claims
- 2341US2008004290A1Anti-Cancer AgentsUNIV QUEENSLAND·Filed 2004·Application pending·0 cites
- 2439US2010267639A1Treatment of osteoarthritisPROMICS PTY LTD·Filed 2010·Application pending·0 cites
- 2536US2004247639A1Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitorsFiled 2001·Application pending·0 cites
- 2632USRE41287ECyclic agonists and antagonists of C5A receptors and G Protein-coupled receptorsPROMICS PTY LTD·Filed 1998·Granted Apr 27, 2010·1 cites·54 claims
- 2732US2006173073A1Microfine zinc-glycerol complexesPURE PHARAMACEUTICALS INC·Filed 2003·Application pending·0 cites
- 2827US9868763B2Modulators of protease activated receptorsFAIRLIE DAVID·Filed 2012·Granted Jan 16, 2018·0 cites·7 claims
- 2922US10245262B2Immunological reagents and uses thereforUNIV QUEENSLAND·Filed 2015·Granted Apr 2, 2019·0 cites·20 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →